Domon H, Isono T, Hiyoshi T, Tamura H, Sasagawa K, Maekawa T
Microbiol Spectr. 2021; 9(2):e0031821.
PMID: 34468195
PMC: 8557819.
DOI: 10.1128/Spectrum.00318-21.
Domon H, Maekawa T, Yonezawa D, Nagai K, Oda M, Yanagihara K
Antimicrob Agents Chemother. 2018; 62(11).
PMID: 30181369
PMC: 6201085.
DOI: 10.1128/AAC.00161-18.
Ovetchkine P, Rieder M
Paediatr Child Health. 2014; 18(6):311-6.
PMID: 24421702
PMC: 3680256.
Kang C, Baek J, Jeon K, Kim S, Chung D, Peck K
J Clin Microbiol. 2012; 50(12):4175-7.
PMID: 23052301
PMC: 3502956.
DOI: 10.1128/JCM.01642-12.
Zahner D, Zhou X, Chancey S, Pohl J, Shafer W, Stephens D
Antimicrob Agents Chemother. 2010; 54(8):3516-9.
PMID: 20498319
PMC: 2916318.
DOI: 10.1128/AAC.01756-09.
Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin.
Oncu S
Ther Clin Risk Manag. 2008; 3(3):441-8.
PMID: 18488076
PMC: 2386358.
Clinical applications of azithromycin microspheres in respiratory tract infections.
Blasi F, Aliberti S, Tarsia P
Int J Nanomedicine. 2008; 2(4):551-9.
PMID: 18203423
PMC: 2676803.
Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
Jenkins S, Brown S, Farrell D
Ann Clin Microbiol Antimicrob. 2008; 7:1.
PMID: 18190701
PMC: 2262084.
DOI: 10.1186/1476-0711-7-1.
Macrolide resistance in Streptococcus pneumoniae: Fallacy or fact?.
Conly J, Johnston B
Can J Infect Dis. 2007; 13(1):13-6.
PMID: 18159367
PMC: 2094850.
DOI: 10.1155/2002/501543.
Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremia.
Neuman M, Kelley M, Harper M, File Jr T, Camargo Jr C
J Emerg Med. 2007; 32(4):349-57.
PMID: 17499686
PMC: 2034392.
DOI: 10.1016/j.jemermed.2006.08.014.
Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.
Swainston Harrison T, Keam S
Drugs. 2007; 67(5):773-92.
PMID: 17385947
DOI: 10.2165/00003495-200767050-00010.
Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management.
Fuller J, McGeer A, Low D
Eur J Clin Microbiol Infect Dis. 2005; 24(12):780-8.
PMID: 16344922
DOI: 10.1007/s10096-005-0059-x.
Erythromycin-nonsusceptible Streptococcus pneumoniae in children, 1999-2001.
McEllistrem M, Adams J, Shutt K, Sanza L, Facklam R, Whitney C
Emerg Infect Dis. 2005; 11(6):969-72.
PMID: 15963300
PMC: 3367581.
DOI: 10.3201/eid1106.050119.
Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.
Shams W, Evans M
Drugs. 2005; 65(7):949-91.
PMID: 15892589
PMC: 7100689.
DOI: 10.2165/00003495-200565070-00004.
Role of beta-lactam agents in the treatment of community-acquired pneumonia.
Garau J
Eur J Clin Microbiol Infect Dis. 2005; 24(2):83-99.
PMID: 15696306
DOI: 10.1007/s10096-005-1287-9.
Antimicrobial therapy of community-acquired pneumonia.
File Jr T, Niederman M
Infect Dis Clin North Am. 2004; 18(4):993-1016, xi.
PMID: 15555836
PMC: 7118969.
DOI: 10.1016/j.idc.2004.07.011.
Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern.
File Jr T
Am J Med. 2004; 117 Suppl 3A:39S-50S.
PMID: 15360096
PMC: 7147208.
DOI: 10.1016/j.amjmed.2004.07.007.
New developments in antibacterial choice for lower respiratory tract infections in elderly patients.
Ferrara A, Fietta A
Drugs Aging. 2004; 21(3):167-86.
PMID: 14979735
DOI: 10.2165/00002512-200421030-00003.
What Is the Clinical Impact of Macrolide Resistance?.
Lonks J
Curr Infect Dis Rep. 2004; 6(1):7-12.
PMID: 14733843
DOI: 10.1007/s11908-004-0018-1.
Community-acquired pneumonia.
File T
Lancet. 2003; 362(9400):1991-2001.
PMID: 14683661
PMC: 7119317.
DOI: 10.1016/S0140-6736(03)15021-0.